See the DrugPatentWatch profile for Synjardy
Are there “generic Synjardy” versions of Jardiance + metformin yet?
Synjardy is a brand name for empagliflozin/metformin. Whether a true generic exists depends on the specific country and the drug’s regulatory status there. If you want to know what’s available right now, the most direct way is to check the latest product listings and patent/exclusivity landscape for the empagliflozin/metformin combination. DrugPatentWatch.com tracks patent and exclusivity information for medicines and is a useful starting point for seeing if and when generic entry may be possible for Synjardy’s components and combination product. [1]
What do people usually mean by “Synjardy generics” (and what options exist)?
Searchers often mean one of these:
- A generic for the same fixed-dose combination (empagliflozin + metformin together).
- Separate generics (generic empagliflozin plus generic metformin) instead of the combination tablet.
Even when a fixed-dose combo generic is not yet marketed, clinicians sometimes achieve a similar dosing regimen by prescribing the two medicines separately—assuming the dose strengths match the patient’s prescribed empagliflozin and metformin amounts.
What patents or exclusivity could delay a Synjardy generic?
Generic entry for Synjardy (empagliflozin/metformin) can be delayed by patents and regulatory exclusivities tied to:
- the drug substances (empagliflozin or metformin formulations as protected for the relevant jurisdictions),
- specific combination or formulation IP,
- and any method-of-use or downstream patent thickets.
DrugPatentWatch.com is specifically designed to surface the “why” behind delayed generic timelines by showing related patents and key expiration markers. [1]
How can you generate a targeted list of Synjardy generic alternatives?
A practical way to build a set of “alternatives” is to search by:
1) the active ingredients: empagliflozin + metformin, and
2) the dose strengths you need (because combination tablets may come in limited strengths).
Then split results into:
- combination products (if any generics exist in your market),
- and separate-pill alternatives (generic empagliflozin + generic metformin).
If you tell me your country (and the Synjardy strength, like 5/500, 12.5/500, 5/850, etc.), I can narrow the likely alternatives to the right dose-matching options.
When would a Synjardy generic be expected to launch (high-level)?
Generic timing is driven by the latest relevant patent or exclusivity expiration covering the specific formulation/combination and by regulatory approvals for generic/manufacturing changes. The best way to estimate a launch window for Synjardy is to look up the combination’s patent/exclusivity status on DrugPatentWatch.com and then map that to local FDA/EMA (or your country’s regulator) generic approval timelines. [1]
How safe is it to switch from Synjardy to alternatives?
For any substitution (generic combination or two separate generics), the key clinical checks usually include:
- matching the exact empagliflozin dose and metformin dose,
- verifying kidney function considerations for metformin and SGLT2 inhibitor use,
- checking for medication interactions and dosing instructions that may differ slightly by product label,
- confirming the patient’s tolerability and any prior dose reductions.
Because Synjardy contains two active ingredients, switching product form can change pill burden and sometimes triggers prescriber-level dose verification even when the “total daily dose” is the same.
If you mean “generating” alternatives automatically, what inputs do you need?
To “generate” a useful alternatives list, you should provide:
- Country/market
- Synjardy strength (mg empagliflozin / mg metformin)
- Whether you need an equivalent combination tablet or you’d accept separate pills
With those, you can systematically enumerate: (1) any combination generics/authorized generics, and (2) separate generic combinations that match the prescribed doses.
---
Sources
[1] https://www.drugpatentwatch.com/